300519 新光药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.7686.5036.0187.55812.764
总资产报酬率 ROA (%)4.4836.0265.4776.81711.514
投入资产回报率 ROIC (%)4.7516.4836.0007.53412.721

边际利润分析
销售毛利率 (%)46.06438.76133.82841.27451.853
营业利润率 (%)31.83824.44421.42527.41636.019
息税前利润/营业总收入 (%)31.00619.71414.32420.07032.956
净利润/营业总收入 (%)27.85020.42918.82623.80030.960

收益指标分析
经营活动净收益/利润总额(%)89.43489.96788.06091.07096.510
价值变动净收益/利润总额(%)7.7878.8778.5425.5673.436
营业外收支净额/利润总额(%)0.127-2.266-0.596-1.330-0.797

偿债能力分析
流动比率 (X)16.76017.16310.97210.1869.192
速动比率 (X)16.13216.1959.9909.2608.670
资产负债率 (%)6.0535.9158.7119.27410.322
带息债务/全部投入资本 (%)-0.502-0.625-0.746-0.790-0.878
股东权益/带息债务 (%)-19,842.222-15,946.831-13,370.649-12,626.621-11,355.291
股东权益/负债合计 (%)1,552.1281,590.7481,047.996978.294868.758
利息保障倍数 (X)-35.534-4.707-2.054-2.873-11.862

营运能力分析
应收账款周转天数 (天)13.61015.07314.65422.49620.345
存货周转天数 (天)84.589124.730143.048133.26498.820